65
Participants
Start Date
April 30, 2009
Primary Completion Date
December 31, 2011
Study Completion Date
April 30, 2012
EC0489, Injection
PART A: Dose escalation from a starting dose of 1.0 mg/m2 IV bolus on Monday, Wednesday, and Friday Weeks 1 and 3 of a 4-week cycle to the Maximum Tolerated Dose (MTD)
EC20
20-25 mCi 99mTc-EC20 administered IV bolus 1-2 hours prior to imaging and at end of study for subjects who received 1 cycle or more of EC0489.
EC0489, Injection
PART B: Once PART A MTD is determined, PART B will begin. Dose escalation from a starting dose of 4.2 mg/m2 IV bolus once weekly in a 4-week cycle to the Maximum Tolerated Dose (MTD).
Center for Cancer and Blood Disorders, Bethesda
Greenebaum Cancer Center - University of Maryland, Baltimore
Horizon Oncology Center, Lafayette
Providence Cancer Institute, Southfield
Barbara Ann Karmanos Cancer Institute - Wayne State University, Detroit
Great Lakes Cancer Institute - Michigan State University, Lansing
Lead Sponsor
Endocyte
INDUSTRY